Sign in

Steven Tong

@steventong.bsky.social
4.4K followers 186 following 310 posts

Infectious diseases, clinical trials, staphylococcus and streptococcus. Reader and runner. Go Hawks!

PostsRepliesMedia
Steven Tong @steventong.bsky.social · 29/09/2026
The next Clarity commentary. On the SNAP trial. Neither I nor @gurujosh.bsky.social had anything to do with this commentary (deliberately). Conclusions though are in line with my interpretation of the data. i.e., use cefazolin for MSSA bacteremia. @angelahuttner.bsky.social @cmicomms.bsky.social
193
Reposted by Steven Tong
CMI Communications @cmicomms.bsky.social · 20/09/2026
🎙️ Just published 'Does oseltamivir harm critically ill patients? The REMAP-CAP results' Hosted by Erin McCreary, PharmD & Josh Davis with invited guests Steve Webb & Steven Tong 🌟 Listen on #Communicable ow.ly/pJAO50ZOfK8 or on #Breakpoints ow.ly/p8Ti50ZOfK9 #IDSky #ViroSky #flu
ow.ly
Communicable E63: Does oseltamivir harm critically ill patients? The REMAP-CAP results | Communicable
1145
Reposted by Steven Tong
CMI Communications @cmicomms.bsky.social · 17/09/2026
📣 New #Communicable / #Breakpoints drops Mon 21 Sep! Erin McCreary, PharmD & Josh Davis are joined by Steve Webb & Steven Tong to discuss REMAP-CAP results suggesting that oseltamivir may harm critically ill patients, while also highlighting the importance and impact of RCTs. #IDSky #ViroSky #flu
0127
Reposted by Steven Tong
IDSA @idsainfo.bsky.social · 09/09/2026
IDSA and ESCMID have released Part 1 of new consensus statements for Staphylococcus aureus bacteremia, introducing a risk-based approach to support diagnostic evaluation and more individualized treatment decisions. 📄: www.idsociety.org/practice-guidelin…
1103
Reposted by Steven Tong
Angela Huttner @angelahuttner.bsky.social · 09/09/2026
Hi Gabriele! Guess what- with @germhuntermd.bsky.social & quite a few others, we are gearing up to launch an #IDjournalclub on Bsky and it looks like this paper is the one we'll start with. 😊 We will get that going soooon!! (Also, Communicable will work on a follow-up POET2 ep!) #IDSky #MedSky
3224
Steven Tong @steventong.bsky.social · 16/08/2026
Come along. This will be a great course in an amazing location!
011
Reposted by Steven Tong
CMI Communications @cmicomms.bsky.social · 11/08/2026
📣We rely more & more on #AI for literature review So how did 6 large language models compare to humans when extracting data from #RCTs for a systematic review? Not very well: overall #LLM concordance was 0.58-0.75. #IDSky @steventong.bsky.social @seanong.bsky.social cmi-comms.org/article/S295...
cmi-comms.org
A proof-of-concept performance evaluation of six large language models for semiautomated data extraction in a systematic review on infectious diseases clinical trials
Large language models (LLMs) are increasingly being used in the systematic review process. Our objective was to explore data extraction performance of six LLMs from a published systematic review of in...
1128
Reposted by Steven Tong
Ouli Xie @ouli-xie.bsky.social · 04/08/2026
Can Group C/G Streptococcus (Streptococcus dysgalactiae subsp. equisimilis, SDSE) become penicillin resistant? We report a case in an individual on prolonged penicillin prophylaxis. doi.org/10.1128/aac.... @steventong.bsky.social @thedohertyinst.bsky.social 🧵👇
doi.org
Penicillin-resistant Streptococcus dysgalactiae subsp. equisimilis and the association with penicillin-binding protein mutations: a population genotypic and phenotypic study | Antimicrobial Agents and Chemotherapy
Streptococcus dysgalactiae subspecies equisimilis (SDSE, commonly referred to as Group C/G Streptococcus) is increasingly recognized as a cause of serious human disease (1). SDSE is closely related to Streptococcus pyogenes with overlapping disease manifestations (1, 2). Incidence of invasive SDSE disease is comparable or even exceeds that of S. pyogenes in some countries, but surveillance lags behind that of its more well-studied relative (2–4).
122
Steven Tong @steventong.bsky.social · 24/07/2026
This course will be great! In Malta too - still warm in November. COI: I'm one of the conveners. Join us!
000
Steven Tong @steventong.bsky.social · 22/06/2026
The SNAP Trial Exemplifies What EBM Should Look Like: www.sensible-med.com/p/the-snap-t... #IDSky
sensible-med.com
The SNAP Trial Exemplifies What EBM Should Look Like
It's always worth showing properly designed and conducted trials--though it's bad for pageviews. Nonetheless, SNAP authors show the way to answering questions in biomedicine
082
Reposted by Steven Tong
José Molina @josemolinagb.bsky.social · 17/06/2026
The SNAP trial domain on cefazolin vs cloxacillin for MSSA bacteremia is finally published! www.nejm.org/doi/full/10.... Cefazolin is already the new standard! #IDsky #AMSsky
0186
Reposted by Steven Tong
Doherty Institute @thedohertyinst.bsky.social · 17/06/2026
A landmark international clinical trial (SNAP Trial) has identified the optimal antibiotics for golden staph bloodstream infections, a breakthrough that is set to reshape treatment for the life-threatening condition. bit.ly/44eY8Kg
doherty.edu.au
Global clinical trial reveals safest, most effective antibiotics for golden staph bloodstream infections
A landmark international clinical trial has identified the optimal antibiotics for golden staph bloodstream infections, a breakthrough that is set to reshape treatment for the life-threatening condition.
043
Reposted by Steven Tong
NEJM.org @nejm.org · 17/06/2026
In the SNAP trial, cefazolin was noninferior to flucloxacillin or cloxacillin with respect to 90-day mortality in patients with methicillin-susceptible Staphylococcus aureus bacteremia and had fewer nephrotoxic effects. Read the full trial results: nej.md/4vL0M6m
The image is a graph showing the posterior probability distribution of the treatment effect for cefazolin versus (flu)cloxacillin regarding 90-day all-cause mortality in the Treatment Policy Strategy population. The x-axis is labeled "Odds ratio (estimand 1)" ranging from 0.4 to 1.5, and the y-axis is labeled "Cefazolin (adults)." The distribution is depicted as a light blue curve, with credible intervals marked at 0.95, 0.99, and 1, indicated by darker shades of blue. A vertical dashed line is at the odds ratio of 1.2.
01813
Reposted by Steven Tong
Antibiotic Steward 🅱️C🆔🅿️🌟 @absteward.bsky.social · 17/06/2026
🔥Just published 🔥NEJM SNAP RCT In patients with MSSA bacteremia, cefazolin was noninferior to flucloxacillin or cloxacillin with respect to 90-day mortality and was associated with a lower incidence of acute kidney injury. #idsky www.nejm.org/doi/full/10....
nejm.org
Cefazolin for Methicillin-Susceptible Staphylococcus aureus Bacteremia | NEJM
Staphylococcus aureus bacteremia is associated with high mortality. Whether cefazolin or an antistaphylococcal penicillin should be preferred for the treatment of methicillin-susceptible S. aureus ...
03115
Reposted by Steven Tong
Michael Marks @drmichaelmarks.bsky.social · 17/06/2026
Excited 1st SNAP result out @thelancet.com PSSA: Fluclox v BenPen thelancet.com/journals/lancet/article/PIIS0140-6736(26)00761-0/fulltext @nejm.org MSSA: Fluclox v Cefazolin nejm.org/doi/full/10.1056/NEJMoa2506905 Should change practice globally Privilege to help deliver trial with fantastic team
helancet.com
1208
Steven Tong @steventong.bsky.social · 16/06/2026
Great post @apsmunro.bsky.social! Doing more is such a natural reaction. But even 'benign' interventions may likely be harmful when tested properly. I'm yet to know of a trial for sepsis where adding antibiotics has been beneficial (outside of TB where we do it to prevent emergence of resistance).
1148
Reposted by Steven Tong
Antibiotic Steward 🅱️C🆔🅿️🌟 @absteward.bsky.social · 26/05/2026
Honored to contribute to this peer-reviewed commentary in CMI Communications alongside an incredible panel of ID physicians and clinical trialists discussing some of the top infectious diseases papers of 2025. #idsky www.cmi-comms.org/article/S295...
183
Steven Tong @steventong.bsky.social · 17/05/2026
This is a really helpful graphic summary of the Andes virus outbreak. #IDSky
0133
Steven Tong @steventong.bsky.social · 16/05/2026
ESCMID 2026 highlights Dalbavancin PK (DOTS‑PK) – Two doses may not be enough High protein binding and wide inter‑patient variability: 1/3 patients may be sub‑therapeutic by day 22 Bottom line: Consider monitoring levels or adding a third dose in complex infections clarityinitiative.org/home
clarityinitiative.org
Clarity Initiative
Clarity Initiative offers clinical literature appraisal and research education in infectious diseases, enhancing knowledge through courses and resources.
1122
Reposted by Steven Tong
Gabriele Pollara @gpollara.bsky.social · 14/05/2026
So good. Have spent years fighting this fight, with hand tied behind my back by lack of great evidence. This study is going to get quoted and cited in microbiology MDTs the world over +++ #IDSky #ClinMicro #AMR
1176
Steven Tong @steventong.bsky.social · 14/05/2026
ESCMID 2026 highlights COBRA Trial – One day is enough Dutch RCT: 1 day of antibiotics after ERCP drainage for cholangitis was non‑inferior to 4–7 days. Bottom line: Antibiotic durations can safely be much shorter once source control is achieved. #IDSky clarityinitiative.org/escmid-2026-...
clarityinitiative.org
Clarity Initiative
Clinical Literature Appraisal and Research education in InfecTious diseases
13117
Steven Tong @steventong.bsky.social · 14/05/2026
Highlights from ESCMID Global 2026? @gurujosh.bsky.social asked CLARITY faculty: @angelahuttner.bsky.social @erinmccreary.bsky.social @marcbonten.bsky.social @seanong.bsky.social @ashabowen.bsky.social and others (not on BlueSky). #IDSky clarityinitiative.org/escmid-2026-... Any that we missed?
clarityinitiative.org
Clarity Initiative
Clinical Literature Appraisal and Research education in InfecTious diseases
2125
Reposted by Steven Tong
CMI Communications @cmicomms.bsky.social · 08/05/2026
Our collaboration episode with Breakpoints covering the trials from the ESCMID Global session 'The trial run' is out now! share.transistor.fm/s/e2a9aee4 🎙️✨ @erinmccreary.bsky.social @gurujosh.bsky.social @jesusrbano.bsky.social #IDSky #clinmicro
share.transistor.fm
Communicable E52: ESCMID Global Trials, PETER PEN and ASTARTE | Communicable | Episode 52
In this collaborative episode of Breakpoints and Communicable, the hosts revisit the “trial run” session from ESCMID Global, a format designed to facilitate critical discussion of major infectious dis...
1129
Reposted by Steven Tong
Antibiotic Steward 🅱️C🆔🅿️🌟 @absteward.bsky.social · 08/05/2026
Long awaited! 🆕💥🟢REMAP-CAP For critically and noncritically ill hospitalized patients with COVID-19, ivermectin was unlikely to improve the primary composite outcome of organ support-free days and hospital survival #idsky journals.lww.com/ccmjournal/f...
journals.lww.com
Ivermectin for Critically and Noncritically Ill... : Critical Care Medicine
between June 11, 2021, and September 9, 2022. Patients: Critically and noncritically ill patients. Interventions: Randomized to ivermectin or no ivermectin (control). Measurements and Main Resu...
072
Steven Tong @steventong.bsky.social · 06/05/2026
We looked at empiric B-lactam antibiotics in MRSA bacteraemia and BC persistence and AKI, using CAMERA2 dataset. Groups: none, early (only empiric B-lactam), late (only after trial enrolment), throughout (empiric and after enrolment). #IDSky www.clinicalmicrobiologyandinfection.org/article/S119...
2125
Reposted by Steven Tong
wiki-guidelines.bsky.social @wiki-guidelines.bsky.social · 23/04/2026
Time for societies to incorporate humility of uncertainty into guidelines Evidence Over Eminence: Rethinking Specialty Guidelines Amid the ATS-IDSA Debate academic.oup.com/cid/article/...
academic.oup.com
Evidence Over Eminence: Rethinking Specialty Guidelines Amid the ATS-IDSA Debate
Brad Spellberg, MD, Bassam Ghanem, PharmD MS BCIDP, Miguel Morante-Ruiz, MD, Émilie Bortolussi-Courval, RN PhD, Anil N Makam, MD MAS, Zeynep Ergenc, MD, Ni
061
Reposted by Steven Tong
Antibiotic Steward 🅱️C🆔🅿️🌟 @absteward.bsky.social · 21/04/2026
🔥 Late Breakers SNAP platform RCT| Adjunctive Clindamycin in S.aureus bacteraemia ❌ No mortality benefit 90d mortality:16.9% vs 15.2% aOR 1.16 (CrI cross 1) 📊PPSup(~7%)→Futility threshold reached ⚠️ICU subgp:numerically worse with clinda ⚖️CDAD:no # (~2%)😯 #ESCMIDGlobal2026 #idsky
1239
Reposted by Steven Tong
CMI Communications @cmicomms.bsky.social · 06/03/2026
📣 New CLARITY articles by Erin McCreary, PharmD & Ahmad Mourad are out to help us understand the GAMECHANGER trial & #cefiderocol The first notes a mortality signal among metallo-β-lactamase–producing infections... #IDSky #clinmicro ow.ly/GAqx50Yq6uh
ow.ly
How do we win? The GAME CHANGER trial
034
Steven Tong @steventong.bsky.social · 05/03/2026
And @gurujosh.bsky.social and I just recorded a podcast with Scott Berry for 'In the Interim'. We discuss the SNAP journey so far. www.berryconsultants.com/resources/po.... Episode should drop in 2-3 weeks. Will post again when it does. @thedohertyinst.bsky.social #IDSky
berryconsultants.com
In the Interim... | A Podcast by Berry Consultants
A podcast on statistical science and clinical trials.
0121
Steven Tong @steventong.bsky.social · 04/03/2026
Just woke up and checked emails to see that 8 new participants recruited to #SNAP_Trial in the past 8 hours! While a number of domains have closed (PSSA, MSSA, adjunctive clindamycin) we continue to recruit to other domains. Beyond 5,800 total participants now. @gurujosh.bsky.social
1161
Steven Tong @steventong.bsky.social · 02/03/2026
We were absolutely the beneficiaries of your visit @angelahuttner.bsky.social! We learnt so much about scientific communication and publishing, gender equity in medicine and science, and UTIs! (each was the focus of a talk / discussion Angela led). #IDSky
050
Steven Tong @steventong.bsky.social · 27/02/2026
Awesome to have @angelahuttner.bsky.social visiting in Australia!
170
Reposted by Steven Tong
Antibiotic Steward 🅱️C🆔🅿️🌟 @absteward.bsky.social · 13/02/2026
With ESCMID Global quickly approaching! To help you spread the word and get involved, check out ESCMID Global 2026 Promotional Toolkit The official hashtag for the congress this year is #ESCMIDGlobal2026 on all social media channels. #IDSky www.escmid.org/congress-eve...
escmid.org
Promotional Toolkit
ESCMID Global (formerly ECCMID): an annual congress bringing together experts and specialists in Clinical Microbiology and Infectious Diseases.
065
Reposted by Steven Tong
Josh Davis @gurujosh.bsky.social · 05/02/2026
My top 10 ID papers for 2025. Full citations and descriptions available at clarityinitiative.org/hot-takes Also see/hear our Communicable podcast episode on this at communicable.transistor.fm/episodes/com... What were your top 10? Any thoughts about what I missed welcome! #IDSky #Top10papers
13210
Reposted by Steven Tong
Anita Williams @catanita.bsky.social · 28/01/2026
Medical research spending has a positive return on investment; for every $ invested there's an estimated $4 return. Beyond economics, delays hold up medical innovations Australians deserve better If you agree, please sign the petition to let #auspol leaders know why medical research matters #NHMRC
0113
Reposted by Steven Tong
CMI Communications @cmicomms.bsky.social · 25/01/2026
🎙️ Just published Communicable E45: Top infectious diseases papers in 2025 Hosted by Josh Davis & Emily McDonald w/ invited guest Steven Tong Listen on #Communicable: share.transistor.fm/s/9e626f2a #IDSky #clinmicro
share.transistor.fm
Communicable | Communicable Episode 45: Top infectious diseases papers in 2025
In this episode of Communicable, Josh Davis (Newcastle, Australia) and Emily McDonald (Montreal, Canada), plus invited guest, Steven Tong (Melbourne, Australia)—all practicing physicians and clinical trialists— assemble to discuss some of their ‘top infectious diseases papers published in 2025’....
0126
Reposted by Steven Tong
CMI Communications @cmicomms.bsky.social · 22/01/2026
📣 New #Communicable drops Mon 26 Jan! In our last episode, we brought you some favorite #clinmicro papers of 2025. We continue this thread in our next episode with top ID papers of 2025, picked by our editors, Josh Davis & Emily McDonald and guest, Steven Tong. ⭐ Tune in Monday🎙️ #IDSky
085
Reposted by Steven Tong
Jason Trubiano @trubianojason.bsky.social · 19/01/2026
💊Drug Hypesensitivity Symposium 2026 - #DHS2026 Registrations are now open for our amazing 3-day #drugallergy & #antibioticallergy program in Melbourne 23-25th October 2026. Stellar international🌏speaker lineup. @allergy-eaaci.bsky.social @thedohertyinst.bsky.social ➡️https://dhs2026.org/
044
Steven Tong @steventong.bsky.social · 18/01/2026
I see patients with TB every week. I can access modern diagnostics and treatments. Reading this book reminded me that is not the case in much of the world. TB kills 1.25 million per year. A disease of injustice. Everything Is Tuberculosis: John Green www.goodreads.com/book/show/22...
goodreads.com
Everything Is Tuberculosis: The History and Persistence…
Tuberculosis has been entwined with humanity for millen…
1176
Reposted by Steven Tong
Anita Williams @catanita.bsky.social · 15/01/2026
Exciting news - there's a spot open in the #IDepi team at @thekidsau.bsky.social ! Prof Chris Blyth is looking for a Research Officer to work on influenza research 1-year initial contract based in Perth Slight bias (my team/boss) but it's a fantastic opportunity! #EpiSky #AcademicSky #AusAcademia
thekids.csod.com
Research Officer
The OpportunityHere at The Kids our vision is simple; Happy, Healthy Kids!The Infectious Diseases Epidemiology Team is dedicated to reducing the burd...
021
Reposted by Steven Tong
Prof. Michael Fuhrer @michaelsfuhrer.bsky.social · 13/01/2026
Now I'll have a look at how Covid-19 deaths have changed over time. See the quoted thread for discussion of how cases, emergency department visits, and hospitalizations have changed over time. 1/
293
Steven Tong @steventong.bsky.social · 12/01/2026
Pretty cool that Robin Patel picks Ouli Xie's @lancetmicrobe.bsky.social paper on SDSE and S pyogenes as one of her top 3 clinical microbiology papers for 2025! As expected, Robin does a great job explaining the paper. www.thelancet.com/journals/lan... @onisillos.bsky.social
thelancet.com
Invasive Streptococcus dysgalactiae subspecies equisimilis compared with Streptococcus pyogenes in Australia, 2011–23, and the emergence of a multi-continent stG62647 lineage: a retrospective clinical...
We identified a substantial burden of invasive SDSE, dominated by the emergent stG62647 lineage. The contrasting epidemiology between species in the different Australian regions, during COVID-19 NPIs,...
2157
Steven Tong @steventong.bsky.social · 01/01/2026
The 3rd and 4th commentaries on recent ID trials are up on the CLARITY website (we aim to publish in depth reviews of important ID stuies). This time looking at the GAMECHANGER trial: clarityinitiative.org/commentaries... @erinmccreary.bsky.social with Ahmad Mourad @gurujosh.bsky.social #IDSky
clarityinitiative.org
How Do We Win? The GAME CHANGER Trial
Erin K. McCreary, PharmD (1), Ahmad Mourad, MD MHS (2, 3)
0146
Reposted by Steven Tong
JAMA @jama.com · 28/12/2025
The numbers are in. This year's most popular JAMA content spans a range of topics, from coffee and #AFib to #osteoporosis to #SepticShock. What was your favorite article in 2025—and did other readers agree? 🔗 ja.ma/49dIcKr
Collage titled "Most Viewed JAMA 2025," featuring medical diagrams and study results: lung scans, iron absorption, DNA repair, biofilm formation, coffee consumption/abstinence study, and organ system treatments.
042
Reposted by Steven Tong
Antibiotic Steward 🅱️C🆔🅿️🌟 @absteward.bsky.social · 06/12/2025
🆕🔥State of art review article by 🌟 s @drtoddlee.bsky.social @steventong.bsky.social Navigating the Challenges in Staphylococcus aureus Bloodstream Infection: A Practical Guide to Management #idsky #EMIMCC www.sciencedirect.com/science/arti...
4156
Steven Tong @steventong.bsky.social · 04/12/2025
New article about how to manage Staphylococcus aureus bacteremia. Led by Hadar Mudrik-Zohar. Includes @seanong.bsky.social @drtoddlee.bsky.social #IDSky #SNAP_trial www.sciencedirect.com/science/arti...
sciencedirect.com
Navigating the Challenges in Staphylococcus aureus Bloodstream Infection: A Practical Guide to Management
0146
Steven Tong @steventong.bsky.social · 04/12/2025
A reflection on decades of work to improve skin health in remote Australian communities: www.nhmrc.gov.au/about-us/res... @ashabowen.bsky.social @nhmrc.bsky.social @thedohertyinst.bsky.social
nhmrc.gov.au
020
Reposted by Steven Tong
Sean Ong @seanong.bsky.social · 30/11/2025
A group of ID clinical researchers passionate about clinical research and evidence appraisal has just launched the CLARITY initiative (clarityinitiative.org), which aims to improve the generation and interpretation of evidence in ID and Microbiology.
clarityinitiative.org
Clarity Initiative
Clinical Literature Appraisal and Research education in InfecTious diseases
11811
Reposted by Steven Tong
CMI Communications @cmicomms.bsky.social · 01/12/2025
📣 We're thrilled to be part of #CLARITY, an initiative led by Josh Davis @gurujosh.bsky.social & @steventong.bsky.social for physicians, pharmacists & #clinmicro specialists passionate about #clinicalresearch & #evidence appraisal. Join us! 🌱 #IDSky #MedSky #MedEd www.cmi-comms.org/article/S295...
cmi-comms.org
The CLARITY initiative: Clinical Literature Appraisal and Research education in InfecTious diseases and microbiologY
Over the past two decades, the generation and application of clinical evidence in the fields of clinical infectious diseases and microbiology have entered a new era: one in which clinical guidelines a...
1114
Steven Tong @steventong.bsky.social · 01/12/2025
A new #IDSky initiative. #CLARITY. Check out our editorial about it.
080